Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis
To analyse the role of interferon-β or glatiramer acetate in reducing the inflammatory episodes of intra-ocular inflammation in multiple sclerosis-associated uveitis. A study was conducted on a non-randomised, retrospective case series of 13 patients with proven multiple sclerosis and uveitis (minim...
Gespeichert in:
| Veröffentlicht in: | Archivos de la Sociedad Española de Oftalmología 2017-06, Vol.92 (6), p.273-279 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 279 |
|---|---|
| container_issue | 6 |
| container_start_page | 273 |
| container_title | Archivos de la Sociedad Española de Oftalmología |
| container_volume | 92 |
| creator | Velazquez-Villoria, D Macia-Badia, C Segura-García, A Pastor Idoate, S Arcos-Algaba, G Velez-Escola, L García-Arumí, J |
| description | To analyse the role of interferon-β or glatiramer acetate in reducing the inflammatory episodes of intra-ocular inflammation in multiple sclerosis-associated uveitis.
A study was conducted on a non-randomised, retrospective case series of 13 patients with proven multiple sclerosis and uveitis (minimum follow-up, 12 months). All patients were given immunomodulatory treatment (interferon-β or glatiramer acetate) to control the course of the multiple sclerosis. Patients were compared to themselves before initiating the treatment, in order to assess the difference in uveitis episodes. The main outcome measurements were the number of uveitis episodes with/without immunomodulatory treatment.
Uveitis was bilateral in 10 (77%) out of 13 patients. Intermediate uveitis was observed in 11 patients, retinal vasculitis in 3 patients, and one patient was classified as a posterior uveitis. The patients had a mean of 4.15±3.1 episodes of uveitis (range 1-10) during the follow-up period (148.6±84.3 months). When compared to their pre-treatment status, patients on treatment with interferon-β or glatiramer acetate showed a significant decrease of 0.36 episodes of ocular inflammation per year (P=.02). Mild side effects related to immunomodulatory treatment were observed in 6 (46%) patients, 3 (23%) patients with a flu-like syndrome, and 3 (23%) patients with a skin rash.
Interferon β or glatiramer acetate could be effective in reducing the uveitis episodes in patients with multiple sclerosis-associated uveitis, and was well tolerated in most patients. |
| doi_str_mv | 10.1016/j.oftal.2016.11.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1867538208</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1867538208</sourcerecordid><originalsourceid>FETCH-LOGICAL-p560-ebdbdad0b717b43f60f54ca2b51c777509636c80d19c1e948026f2c71ac2739a3</originalsourceid><addsrcrecordid>eNo1kM1KxDAAhIMg7rr6BILk6KU1P9skPcqy_sCCl72XNE3cLElTk3Slr-WD-EwWXE_DMB8DMwDcYVRihNnjsQwmS1eS2ZQYlwiLC7DEtagLTgRbgOuUjgitKa3FFVgQgYVABC3BaWuMVVJNMBhovR_74EM3OplDnGA-6CiHCX7ZfIC2zzoaHUNf_HzDEOHHTNkovY5QKp1l1jD00I8u28FpmJSb4WRTIVMKys55B8eTttmmG3BppEv69qwrsH_e7jevxe795W3ztCuGiqFCt13byQ61HPN2TQ1DplorSdoKK855hWpGmRKow7XCul7Pk5ghimOpCKe1pCvw8Fc7xPA56pQbb5PSzslehzE1WDBeUUGQmNH7Mzq2XnfNEK2XcWr-r6K_5CJumQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867538208</pqid></control><display><type>article</type><title>Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Velazquez-Villoria, D ; Macia-Badia, C ; Segura-García, A ; Pastor Idoate, S ; Arcos-Algaba, G ; Velez-Escola, L ; García-Arumí, J</creator><creatorcontrib>Velazquez-Villoria, D ; Macia-Badia, C ; Segura-García, A ; Pastor Idoate, S ; Arcos-Algaba, G ; Velez-Escola, L ; García-Arumí, J</creatorcontrib><description>To analyse the role of interferon-β or glatiramer acetate in reducing the inflammatory episodes of intra-ocular inflammation in multiple sclerosis-associated uveitis.
A study was conducted on a non-randomised, retrospective case series of 13 patients with proven multiple sclerosis and uveitis (minimum follow-up, 12 months). All patients were given immunomodulatory treatment (interferon-β or glatiramer acetate) to control the course of the multiple sclerosis. Patients were compared to themselves before initiating the treatment, in order to assess the difference in uveitis episodes. The main outcome measurements were the number of uveitis episodes with/without immunomodulatory treatment.
Uveitis was bilateral in 10 (77%) out of 13 patients. Intermediate uveitis was observed in 11 patients, retinal vasculitis in 3 patients, and one patient was classified as a posterior uveitis. The patients had a mean of 4.15±3.1 episodes of uveitis (range 1-10) during the follow-up period (148.6±84.3 months). When compared to their pre-treatment status, patients on treatment with interferon-β or glatiramer acetate showed a significant decrease of 0.36 episodes of ocular inflammation per year (P=.02). Mild side effects related to immunomodulatory treatment were observed in 6 (46%) patients, 3 (23%) patients with a flu-like syndrome, and 3 (23%) patients with a skin rash.
Interferon β or glatiramer acetate could be effective in reducing the uveitis episodes in patients with multiple sclerosis-associated uveitis, and was well tolerated in most patients.</description><identifier>EISSN: 1989-7286</identifier><identifier>DOI: 10.1016/j.oftal.2016.11.018</identifier><identifier>PMID: 28188020</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>Adult ; Drug Evaluation ; Female ; Glatiramer Acetate - therapeutic use ; Humans ; Immunologic Factors - therapeutic use ; Immunomodulation ; Interferon-beta - therapeutic use ; Male ; Middle Aged ; Multiple Sclerosis, Chronic Progressive - complications ; Multiple Sclerosis, Chronic Progressive - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - complications ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Retinal Vasculitis - drug therapy ; Retinal Vasculitis - etiology ; Retrospective Studies ; Treatment Outcome ; Uveitis - drug therapy ; Uveitis - etiology ; Young Adult</subject><ispartof>Archivos de la Sociedad Española de Oftalmología, 2017-06, Vol.92 (6), p.273-279</ispartof><rights>Copyright © 2017 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28188020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Velazquez-Villoria, D</creatorcontrib><creatorcontrib>Macia-Badia, C</creatorcontrib><creatorcontrib>Segura-García, A</creatorcontrib><creatorcontrib>Pastor Idoate, S</creatorcontrib><creatorcontrib>Arcos-Algaba, G</creatorcontrib><creatorcontrib>Velez-Escola, L</creatorcontrib><creatorcontrib>García-Arumí, J</creatorcontrib><title>Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis</title><title>Archivos de la Sociedad Española de Oftalmología</title><addtitle>Arch Soc Esp Oftalmol</addtitle><description>To analyse the role of interferon-β or glatiramer acetate in reducing the inflammatory episodes of intra-ocular inflammation in multiple sclerosis-associated uveitis.
A study was conducted on a non-randomised, retrospective case series of 13 patients with proven multiple sclerosis and uveitis (minimum follow-up, 12 months). All patients were given immunomodulatory treatment (interferon-β or glatiramer acetate) to control the course of the multiple sclerosis. Patients were compared to themselves before initiating the treatment, in order to assess the difference in uveitis episodes. The main outcome measurements were the number of uveitis episodes with/without immunomodulatory treatment.
Uveitis was bilateral in 10 (77%) out of 13 patients. Intermediate uveitis was observed in 11 patients, retinal vasculitis in 3 patients, and one patient was classified as a posterior uveitis. The patients had a mean of 4.15±3.1 episodes of uveitis (range 1-10) during the follow-up period (148.6±84.3 months). When compared to their pre-treatment status, patients on treatment with interferon-β or glatiramer acetate showed a significant decrease of 0.36 episodes of ocular inflammation per year (P=.02). Mild side effects related to immunomodulatory treatment were observed in 6 (46%) patients, 3 (23%) patients with a flu-like syndrome, and 3 (23%) patients with a skin rash.
Interferon β or glatiramer acetate could be effective in reducing the uveitis episodes in patients with multiple sclerosis-associated uveitis, and was well tolerated in most patients.</description><subject>Adult</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Glatiramer Acetate - therapeutic use</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunomodulation</subject><subject>Interferon-beta - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis, Chronic Progressive - complications</subject><subject>Multiple Sclerosis, Chronic Progressive - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - complications</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Retinal Vasculitis - drug therapy</subject><subject>Retinal Vasculitis - etiology</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Uveitis - drug therapy</subject><subject>Uveitis - etiology</subject><subject>Young Adult</subject><issn>1989-7286</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1KxDAAhIMg7rr6BILk6KU1P9skPcqy_sCCl72XNE3cLElTk3Slr-WD-EwWXE_DMB8DMwDcYVRihNnjsQwmS1eS2ZQYlwiLC7DEtagLTgRbgOuUjgitKa3FFVgQgYVABC3BaWuMVVJNMBhovR_74EM3OplDnGA-6CiHCX7ZfIC2zzoaHUNf_HzDEOHHTNkovY5QKp1l1jD00I8u28FpmJSb4WRTIVMKys55B8eTttmmG3BppEv69qwrsH_e7jevxe795W3ztCuGiqFCt13byQ61HPN2TQ1DplorSdoKK855hWpGmRKow7XCul7Pk5ghimOpCKe1pCvw8Fc7xPA56pQbb5PSzslehzE1WDBeUUGQmNH7Mzq2XnfNEK2XcWr-r6K_5CJumQ</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Velazquez-Villoria, D</creator><creator>Macia-Badia, C</creator><creator>Segura-García, A</creator><creator>Pastor Idoate, S</creator><creator>Arcos-Algaba, G</creator><creator>Velez-Escola, L</creator><creator>García-Arumí, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201706</creationdate><title>Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis</title><author>Velazquez-Villoria, D ; Macia-Badia, C ; Segura-García, A ; Pastor Idoate, S ; Arcos-Algaba, G ; Velez-Escola, L ; García-Arumí, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p560-ebdbdad0b717b43f60f54ca2b51c777509636c80d19c1e948026f2c71ac2739a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Glatiramer Acetate - therapeutic use</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunomodulation</topic><topic>Interferon-beta - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis, Chronic Progressive - complications</topic><topic>Multiple Sclerosis, Chronic Progressive - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - complications</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Retinal Vasculitis - drug therapy</topic><topic>Retinal Vasculitis - etiology</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Uveitis - drug therapy</topic><topic>Uveitis - etiology</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Velazquez-Villoria, D</creatorcontrib><creatorcontrib>Macia-Badia, C</creatorcontrib><creatorcontrib>Segura-García, A</creatorcontrib><creatorcontrib>Pastor Idoate, S</creatorcontrib><creatorcontrib>Arcos-Algaba, G</creatorcontrib><creatorcontrib>Velez-Escola, L</creatorcontrib><creatorcontrib>García-Arumí, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Archivos de la Sociedad Española de Oftalmología</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Velazquez-Villoria, D</au><au>Macia-Badia, C</au><au>Segura-García, A</au><au>Pastor Idoate, S</au><au>Arcos-Algaba, G</au><au>Velez-Escola, L</au><au>García-Arumí, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis</atitle><jtitle>Archivos de la Sociedad Española de Oftalmología</jtitle><addtitle>Arch Soc Esp Oftalmol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>92</volume><issue>6</issue><spage>273</spage><epage>279</epage><pages>273-279</pages><eissn>1989-7286</eissn><abstract>To analyse the role of interferon-β or glatiramer acetate in reducing the inflammatory episodes of intra-ocular inflammation in multiple sclerosis-associated uveitis.
A study was conducted on a non-randomised, retrospective case series of 13 patients with proven multiple sclerosis and uveitis (minimum follow-up, 12 months). All patients were given immunomodulatory treatment (interferon-β or glatiramer acetate) to control the course of the multiple sclerosis. Patients were compared to themselves before initiating the treatment, in order to assess the difference in uveitis episodes. The main outcome measurements were the number of uveitis episodes with/without immunomodulatory treatment.
Uveitis was bilateral in 10 (77%) out of 13 patients. Intermediate uveitis was observed in 11 patients, retinal vasculitis in 3 patients, and one patient was classified as a posterior uveitis. The patients had a mean of 4.15±3.1 episodes of uveitis (range 1-10) during the follow-up period (148.6±84.3 months). When compared to their pre-treatment status, patients on treatment with interferon-β or glatiramer acetate showed a significant decrease of 0.36 episodes of ocular inflammation per year (P=.02). Mild side effects related to immunomodulatory treatment were observed in 6 (46%) patients, 3 (23%) patients with a flu-like syndrome, and 3 (23%) patients with a skin rash.
Interferon β or glatiramer acetate could be effective in reducing the uveitis episodes in patients with multiple sclerosis-associated uveitis, and was well tolerated in most patients.</abstract><cop>Spain</cop><pmid>28188020</pmid><doi>10.1016/j.oftal.2016.11.018</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1989-7286 |
| ispartof | Archivos de la Sociedad Española de Oftalmología, 2017-06, Vol.92 (6), p.273-279 |
| issn | 1989-7286 |
| language | eng ; spa |
| recordid | cdi_proquest_miscellaneous_1867538208 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Drug Evaluation Female Glatiramer Acetate - therapeutic use Humans Immunologic Factors - therapeutic use Immunomodulation Interferon-beta - therapeutic use Male Middle Aged Multiple Sclerosis, Chronic Progressive - complications Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Relapsing-Remitting - complications Multiple Sclerosis, Relapsing-Remitting - drug therapy Retinal Vasculitis - drug therapy Retinal Vasculitis - etiology Retrospective Studies Treatment Outcome Uveitis - drug therapy Uveitis - etiology Young Adult |
| title | Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A12%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20immunomodulatory%20therapy%20with%20interferon-%CE%B2%20or%20glatiramer%20acetate%20on%20multiple%20sclerosis-associated%20uveitis&rft.jtitle=Archivos%20de%20la%20Sociedad%20Espa%C3%B1ola%20de%20Oftalmolog%C3%ADa&rft.au=Velazquez-Villoria,%20D&rft.date=2017-06&rft.volume=92&rft.issue=6&rft.spage=273&rft.epage=279&rft.pages=273-279&rft.eissn=1989-7286&rft_id=info:doi/10.1016/j.oftal.2016.11.018&rft_dat=%3Cproquest_pubme%3E1867538208%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1867538208&rft_id=info:pmid/28188020&rfr_iscdi=true |